Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Definitive Healthcare (DH) Research & Development (2020 - 2025)

Definitive Healthcare (DH) has disclosed Research & Development for 6 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 10.82% year-over-year to $10.0 million, compared with a TTM value of $34.8 million through Dec 2025, down 4.77%, and an annual FY2025 reading of $34.8 million, down 4.77% over the prior year.
  • Research & Development was $10.0 million for Q4 2025 at Definitive Healthcare, up from $7.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.6 million in Q4 2023 and bottomed at $3.8 million in Q1 2021.
  • Average Research & Development over 5 years is $8.4 million, with a median of $9.1 million recorded in 2022.
  • The sharpest move saw Research & Development surged 103.55% in 2022, then crashed 32.32% in 2024.
  • Year by year, Research & Development stood at $5.7 million in 2021, then soared by 76.22% to $10.1 million in 2022, then grew by 14.22% to $11.6 million in 2023, then decreased by 22.36% to $9.0 million in 2024, then increased by 10.82% to $10.0 million in 2025.
  • Business Quant data shows Research & Development for DH at $10.0 million in Q4 2025, $7.6 million in Q3 2025, and $8.0 million in Q2 2025.